FMP
Tricida, Inc.
TCDA
NASDAQ
Inactive Equity
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
0.108 USD
0 (0%)
About
ceo
Dr. Gerrit Klaerner Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.tricida.com
exchange
NASDAQ
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
CIK
0001595585
ISIN
US89610F1012
CUSIP
89610F101
Address
7000 Shoreline Court
Phone
415 429 7800
Country
US
Employee
57
IPO Date
Jun 28, 2018
Key Executives
